In terms of clinical behavior, a few rare molecular alterations have been linked to aggressive meningioma biology, including oncogenic variants in the TERT promoter region and homozygous deletions of CDKN2A/CDKN2B (14, 15). This evidence concerns the gene TERT and meningioma.